LVMH Recherche and LVMH's beauty R&D group is leveraging California-based Integrated Biosciences' AI and synthetic biology capabilities to fast-track the discovery of anti-aging skin care technologies. Financial terms of the partnership were not disclosed.
Integrated Biosciences pairs AI with optogenetics, the latter of which allows the company's researchers to control and monitor the biological function of individual cells, groups of cells, tissues and organs.
Combined, the company's deep learning models can "virtually screen hundreds of thousands of molecules" to identify chemical compounds with the most promise for modulating age-related biological phenotypes.
The company has already made a name for itself by using AI to identify novel senolytic compounds that clear out senescent cells.
Integrated Biosciences was founded by scientists at MIT, Harvard University and the University of California Santa Barbara; its investors include Sutter Hill Ventures.
“Our partnership with Integrated Biosciences perfectly embodies our vision: to expand the frontiers of scientific discovery, fueling transformative innovations in beauty,” said Bruno Bavouzet, president of LVMH Recherche. “This represents a unique opportunity to evaluate thousands of potential bioactives concurrently, revolutionizing the pace of our research for the benefit of all our brands, amongst them our flagship–Maison Parfums Christian Dior. By combining our skin research expertise with their AI and aging research, we are taking a decisive step in understanding and molecularly addressing age-related cellular pathways.”
“This collaboration with LVMH Recherche, a global leader in luxury consumer product R&D, represents a significant step forward in our shared commitment to combating aging through cutting-edge science,” said Felix Wong, Ph.D., co-founder and CEO of Integrated Biosciences. “We are excited to integrate our proprietary technology platform with LVMH Recherche's scientific programs, leveraging our ability to control biological stress responses to develop novel, targeted bioactive molecules. Our combined efforts have the potential to unlock biologically functional products that could transform how people age.”
